Consistently, the Tpex subset of PD-1+ CD8 TILs from human renal cell carcinoma (RCC) tumors also had a superior ability to proliferate following ex vivo IL-15 treatment, compared with the Ttex subset. This evidence concerns the gene CD8A and renal cell carcinoma.